Department of Microbiology, Molecular Biology, and Biochemistry, University of Idaho, Moscow, ID 83844-3052, USA.
Induction of innate immunity by lipid A mimetics increases survival from H1N1 bird flu?
This study analysed the effect of priming the innate immune system using synthetic lipid A mimetics in a Yersinia pestis murine pulmonary infection model. Two aminoalkyl glucosaminide 4-phosphate (AGP) Toll-like receptor 4 (TLR4) ligands, delivered intranasally, extended time to death or protected against a lethal Y. pestis CO92 challenge. The level of protection was dependent upon the challenge dose of Y. pestis and the timing of AGP therapy. Protection correlated with cytokine induction and a decreased bacterial burden in lung tissue. AGP protection was TLR4-dependent and was not evidenced in transgenic TLR4-deficient mice. AGP therapy augmented with subtherapeutic doses of gentamicin produced dramatically enhanced survival. Combined, these results indicated that AGPs may be useful in protection of immunologically naive individuals against plague and potentially other infectious agents, and that AGP therapy may be used synergistically with other therapies.
Tamiflu is only suitable for a specific virus, not a range of viruses, the trigger of the immunity system in the body defence system will inhabit all attacks.
Not all fats are bad for you after all.
An international team led by scientists from Singapore Immunology Network (SIgN) have discovered a special class of fatty molecules essential for stimulating immune cells.
The fats, which are naturally produced in the thymus, work by activating a unique group of early-responding immune cells which protects the body against infection, allergic reactions, autoimmune diseases and cancer.
These immune cells form first line of defence against infectious and foreign agents, and when stimulated, secrete large amounts of biological chemicals.
They also are capable of influencing the responses of other immune cells in the body.
The finding opens up new opportunities in using these stimulatory fats for therapeutic interventions, such as the development of new vaccines and drugs targeted for autoimmune diseases, said the researchers.
“This discovery is a breakthrough for the field of lipid immunity, a new niche area in immunology that SIgN has recently been developing,” said Professor Paola Castagnoli, Scientific Director of SIgN.
The team was co-led by Professor Gennaro De Libero and Dr Lucia Mori, Senior Principal Investigators at SIgN, which is an agency under the Agency of Science, Technology and Research (A*STAR).
– Contributed by Oogle